Abstract: Vision is arguably our most valued sense, yet approximately 340 million people globally suffer blindness or moderate visual impairment, highlighting the need to further develop and advance treatments for ophthalmic diseases. Glaucoma refers to a group of ocular disorders united by a clinically characteristic optic neuropathy with associated retinal ganglion cell loss. It is one of the most prevalent neurodegenerations globally, the leading cause of irreversible blindness, and affects ~80 million people worldwide (with an estimated further 40 million undiagnosed).